Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Innovation in oncology drug development and regulation (in collaboration with CSCO)

Bottleneck, coping strategy and expectation: Anti-angiogenic therapy in China

Date

20 Nov 2020

Session

Innovation in oncology drug development and regulation (in collaboration with CSCO)

Topics

Clinical Research

Tumour Site

Presenters

Kai Li

Authors

K. Li

Author affiliations

  • Tianjin Medical University Cancer Institute & Hospital, 300060 - Tianjin/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.